{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:47:19Z","timestamp":1784076439958,"version":"3.55.0"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sexual Medicine Reviews"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.sxmr.2016.06.005","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T05:20:04Z","timestamp":1469769604000},"page":"376-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Testosterone Therapy Among Prostate Cancer Survivors"],"prefix":"10.1093","volume":"4","author":[{"given":"Taylor M.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Pastuszak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1016\/j.sxmr.2016.06.005_bib1","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1210\/jc.2005-2847","article-title":"Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline","volume":"91","author":"Bhasin","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2016.06.005_bib2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ucl.2007.08.007","article-title":"The role of testosterone replacement therapy following radical prostatectomy","volume":"34","author":"Khera","year":"2007","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.sxmr.2016.06.005_bib3","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1210\/jc.2007-1245","article-title":"Prevalence of symptomatic androgen deficiency in men","volume":"92","author":"Araujo","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2016.06.005_bib4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1210\/jcem.87.2.8201","article-title":"Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study","volume":"87","author":"Feldman","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2016.06.005_bib5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jcem.86.2.7219","article-title":"Longitudinal effects of aging on serum total and free testosterone levels in healthy men","volume":"86","author":"Harman","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2016.06.005_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.sxmr.2016.06.005_bib7","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamainternmed.2013.6895","article-title":"Trends in androgen prescribing in the United States, 2001 to 2011","volume":"173","author":"Baillargeon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.sxmr.2016.06.005_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1380051","article-title":"Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men","volume":"138","author":"Leifke","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1365-2265.2003.01746.x","article-title":"Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism","volume":"58","author":"Zacharin","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.sxmr.2016.06.005_bib10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.tem.2010.03.002","article-title":"Testosterone deficiency: a risk factor for cardiovascular disease?","volume":"21","author":"Jones","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2016.06.005_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.mayocp.2014.10.011","article-title":"Testosterone therapy and cardiovascular risk: advances and controversies","volume":"90","author":"Morgentaler","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.sxmr.2016.06.005_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.urology.2015.11.034","article-title":"Controversies and advances with testosterone therapy: a 40-year perspective","volume":"89","author":"Morgentaler","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2016.06.005_bib13","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.sxmr.2016.06.005_bib14","doi-asserted-by":"crossref","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.sxmr.2016.06.005_bib15","first-page":"293","article-title":"Studies on prostatic cancer, I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2016.06.005_bib16","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1001\/jama.1996.03540230054035","article-title":"Occult prostate cancer in men with low serum testosterone levels","volume":"276","author":"Morgentaler","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.sxmr.2016.06.005_bib17","first-page":"403","article-title":"The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy","volume":"193","author":"Klap","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00345-011-0793-x","article-title":"Low serum testosterone levels are predictive of prostate cancer","volume":"31","author":"Mearini","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib19","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4111\/kju.2010.51.12.819","article-title":"Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of Korean men","volume":"51","author":"Shin","year":"2010","journal-title":"Korean J Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib20","first-page":"3159","article-title":"Serum testosterone: a potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or\u00a0= 3.0 and <10.0 ng\/mL)","volume":"26","author":"Karamanolakis","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1016\/j.sxmr.2016.06.005_bib21","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.urology.2006.08.1058","article-title":"Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng\/mL or less","volume":"68","author":"Morgentaler","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2016.06.005_bib22","first-page":"824","article-title":"Is low serum free testosterone a marker for high grade prostate cancer?","volume":"163","author":"Hoffman","year":"2000","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib23","doi-asserted-by":"crossref","first-page":"E541","DOI":"10.1111\/j.1464-410X.2012.11232.x","article-title":"Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment","volume":"110","author":"Garc\u00eda-Cruz","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2016.06.005_bib24","first-page":"1935","article-title":"Testosterone as a predictor of pathological stage in clinically localized prostate cancer","volume":"173","author":"Isom-Batz","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib25","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.urology.2008.06.001","article-title":"Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy","volume":"72","author":"Lane","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2016.06.005_bib26","first-page":"1400","article-title":"High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone","volume":"186","author":"Botto","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib27","doi-asserted-by":"crossref","first-page":"E667","DOI":"10.1111\/j.1464-410X.2012.11465.x","article-title":"Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer","volume":"110","author":"Dai","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2016.06.005_bib28","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/j.1464-410X.2010.09816.x","article-title":"Low pretreatment total testosterone (<3 ng\/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer","volume":"107","author":"Xylinas","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2016.06.005_bib29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4111\/kju.2012.53.1.9","article-title":"Usefulness of preoperative serum testosterone as a predictor of extraprostatic extension and biochemical recurrence","volume":"53","author":"Kim","year":"2012","journal-title":"Korean J Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib30","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1002\/cncr.25985","article-title":"Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy","volume":"117","author":"Salonia","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.sxmr.2016.06.005_bib31","first-page":"2178","article-title":"Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer","volume":"174","author":"Teloken","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib32","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.2000.18.4.847","article-title":"Hormonal predictors of prostate cancer: a meta-analysis","volume":"18","author":"Shaneyfelt","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib33","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/jnci\/88.16.1118","article-title":"Prospective study of sex hormone levels and risk of prostate cancer","volume":"88","author":"Gann","year":"1996","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.sxmr.2016.06.005_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.eururo.2006.08.047","article-title":"The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening","volume":"51","author":"Yano","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib35","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-11-2799","article-title":"Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy","volume":"18","author":"Salonia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.sxmr.2016.06.005_bib36","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000354621","article-title":"Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer","volume":"93","author":"Porcaro","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.sxmr.2016.06.005_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00345-012-0856-7","article-title":"Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy","volume":"31","author":"Salonia","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jnci\/djm323","article-title":"Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies","volume":"100","author":"Roddam","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.sxmr.2016.06.005_bib39","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.eururo.2012.05.025","article-title":"Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of Prostate Cancer Events Trial","volume":"62","author":"Muller","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib40","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1158\/1055-9965.EPI-04-0371","article-title":"Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era","volume":"14","author":"Platz","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.sxmr.2016.06.005_bib41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ijc.11572","article-title":"High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study","volume":"108","author":"Stattin","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.sxmr.2016.06.005_bib42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000112602","article-title":"Testosterone levels in benign prostatic hypertrophy and prostate cancer","volume":"80","author":"Mearini","year":"2008","journal-title":"Urol Int"},{"key":"10.1016\/j.sxmr.2016.06.005_bib43","first-page":"905","article-title":"Circulating sex hormones play no role in the association between sexual activity and the risk of prostate cancer","volume":"8","author":"Ahmadi","year":"2011","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2016.06.005_bib44","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1464-410X.2011.10335.x","article-title":"Serum testosterone level as a predictor of biochemical failure after radical prostatectomy for localized prostate cancer","volume":"109","author":"R\u00f8der","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2016.06.005_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1507\/endocrj.48.573","article-title":"Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer","volume":"48","author":"Imamoto","year":"2001","journal-title":"Endocr J"},{"key":"10.1016\/j.sxmr.2016.06.005_bib46","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.eururo.2007.03.052","article-title":"Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy","volume":"52","author":"Yamamoto","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib47","first-page":"868","article-title":"The interpretation of serum prostate specific antigen in men receiving 5\u03b1-reductase inhibitors: a review and clinical recommendations","volume":"176","author":"Marks","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib48","first-page":"441","article-title":"Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men","volume":"159","author":"Cooper","year":"1998","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib49","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4103\/1008-682X.129132","article-title":"Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in\u00a0vitro","volume":"16","author":"Song","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1016\/j.sxmr.2016.06.005_bib50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0090-4295(99)80159-9","article-title":"Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen","volume":"46","author":"Monath","year":"1995","journal-title":"Urology"},{"key":"10.1016\/j.sxmr.2016.06.005_bib51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.eururo.2006.06.034","article-title":"Testosterone and prostate cancer: an historical perspective on a modern myth","volume":"50","author":"Morgentaler","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib53","first-page":"2818","article-title":"Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months","volume":"11","author":"Morgentaler","year":"2014","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2016.06.005_bib54","first-page":"1005","article-title":"Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory","volume":"186","author":"Khera","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib55","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1001\/jama.296.19.2351","article-title":"Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial","volume":"296","author":"Marks","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.sxmr.2016.06.005_bib56","first-page":"2518","article-title":"Serum PSA as a predictor of testosterone deficiency","volume":"10","author":"Rastrelli","year":"2013","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2016.06.005_bib57","first-page":"920","article-title":"Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men","volume":"172","author":"Kaufman","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib58","first-page":"533","article-title":"Testosterone replacement therapy after primary treatment for prostate cancer","volume":"173","author":"Agarwal","year":"2005","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib59","first-page":"1165","article-title":"Testosterone replacement therapy following radical prostatectomy","volume":"6","author":"Khera","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.sxmr.2016.06.005_bib60","first-page":"639","article-title":"Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy","volume":"190","author":"Pastuszak","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"Suppl.","key":"10.1016\/j.sxmr.2016.06.005_bib61","first-page":"e577","article-title":"Testosterone replacement therapy in high risk patients following radical prostatectomy","volume":"183","author":"Sathyamoorthy","year":"2010","journal-title":"J\u00a0Urol"},{"issue":"Suppl.","key":"10.1016\/j.sxmr.2016.06.005_bib62","first-page":"298","article-title":"Analysis of the safety and efficacy of testosterone supplementation following radical prostatectomy","volume":"183","author":"Matsushita","year":"2012","journal-title":"J\u00a0Sex Med"},{"issue":"Suppl.","key":"10.1016\/j.sxmr.2016.06.005_bib63","first-page":"428","article-title":"Analysis of the PSA response after testosterone supplementation in patients who previously received management for their localized prostate cancer [abstract]","volume":"179","author":"Davila","year":"2008","journal-title":"J\u00a0Urol"},{"issue":"Suppl.","key":"10.1016\/j.sxmr.2016.06.005_bib64","first-page":"426","article-title":"Outcomes analysis of testosterone supplementation in hypogonadal men following radical prostatectomy","volume":"179","author":"Nabulsi","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib65","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/cncr.22438","article-title":"Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy","volume":"109","author":"Sarosdy","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.sxmr.2016.06.005_bib66","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1464-410X.2008.07882.x","article-title":"Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations","volume":"103","author":"Morales","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2016.06.005_bib67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ijir.2012.29","article-title":"Testosterone replacement therapy in the setting of prostate cancer treated with radiation","volume":"25","author":"Pastuszak","year":"2013","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.sxmr.2016.06.005_bib68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/bju.12668","article-title":"Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer","volume":"114","author":"Balbontin","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2016.06.005_bib69","first-page":"1271","article-title":"Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer","volume":"194","author":"Pastuszak","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib70","first-page":"2348","article-title":"Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia","volume":"170","author":"Rhoden","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib71","first-page":"1256","article-title":"Testosterone therapy in men with untreated prostate cancer","volume":"185","author":"Morgentaler","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib72","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1464-410X.2011.10193.x","article-title":"Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry","volume":"107","author":"Morales","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.sxmr.2016.06.005_bib73","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1008-682X.160270","article-title":"Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results","volume":"18","author":"Kacker","year":"2016","journal-title":"Asian J Androl"},{"key":"10.1016\/j.sxmr.2016.06.005_bib74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.pcan.4500833","article-title":"Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients","volume":"9","author":"Ferreira","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.sxmr.2016.06.005_bib75","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1423-0127-18-63","article-title":"Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer","volume":"18","author":"Chuu","year":"2011","journal-title":"J\u00a0Biomed Sci"},{"key":"10.1016\/j.sxmr.2016.06.005_bib76","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ncponc1180","article-title":"Intermittent androgen blockade should be regarded as standard therapy in prostate cancer","volume":"5","author":"Seruga","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib77","first-page":"4315","article-title":"A\u00a0mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy","volume":"61","author":"Gregory","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2016.06.005_bib78","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/mend.12.7.0136","article-title":"Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest","volume":"12","author":"Kokontis","year":"1998","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib79","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-0-387-69080-3_21","article-title":"Castration-recurrent prostate cancer is not androgen-independent","volume":"617","author":"Mohler","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib80","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2016.06.005_bib81","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/eem.09.34","article-title":"Androgen receptor abnormalities in castration-recurrent prostate cancer","volume":"4","author":"Nacusi","year":"2009","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.sxmr.2016.06.005_bib82","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.sxmr.2016.06.005_bib83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcb.10683","article-title":"Ras signaling in prostate cancer progression","volume":"91","author":"Weber","year":"2004","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.sxmr.2016.06.005_bib84","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.sxmr.2016.06.005_bib85","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/pros.22504","article-title":"Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer","volume":"72","author":"Isaacs","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.sxmr.2016.06.005_bib86","doi-asserted-by":"crossref","first-page":"11802","DOI":"10.1073\/pnas.93.21.11802","article-title":"Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride","volume":"93","author":"Umekita","year":"1996","journal-title":"PNAS"},{"key":"10.1016\/j.sxmr.2016.06.005_bib87","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4161\/cc.6.6.4028","article-title":"Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation","volume":"6","author":"Vander Griend","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.sxmr.2016.06.005_bib88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jmcb\/mjq052","article-title":"Prevention of DNA re-replication in eukaryotic cells","volume":"3","author":"Truong","year":"2011","journal-title":"J\u00a0Mol Cell Biol"},{"key":"10.1016\/j.sxmr.2016.06.005_bib89","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/1097-0142(19940701)74:1<100::AID-CNCR2820740118>3.0.CO;2-K","article-title":"Oral etoposide in the treatment of hormone-refractory prostate cancer","volume":"74","author":"Hussain","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.sxmr.2016.06.005_bib90","doi-asserted-by":"crossref","first-page":"269ra2","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.sxmr.2016.06.005_bib91","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1210\/jc.2004-0801","article-title":"Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in\u00a0vitro and in\u00a0vivo","volume":"90","author":"Hatzoglou","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Sexual Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052116300269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2050052116300269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T19:36:30Z","timestamp":1672774590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2050052116300269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S2050052116300269"],"URL":"https:\/\/doi.org\/10.1016\/j.sxmr.2016.06.005","relation":{},"ISSN":["2050-0521"],"issn-type":[{"value":"2050-0521","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Testosterone Therapy Among Prostate Cancer Survivors","name":"articletitle","label":"Article Title"},{"value":"Sexual Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sxmr.2016.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}